Literature DB >> 8784072

Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro.

N Chegini1, H Rong, Q Dou, S Kipersztok, R S Williams.   

Abstract

The objective of the present study was to determine whether GnRH and GnRH receptor are expressed in myometrium and leiomyomata, and if GnRH analogs alone or in the presence of ovarian steroids can modulate the rate of DNA synthesis, proliferation, and transforming growth factor-beta 1 (TGF beta 1) production in myometrial smooth muscle cells in vitro. Reverse transcription-PCR revealed that leiomyomata, unaffected myometrium, and isolated myometrial smooth muscle cells express GnRH and GnRH receptor messenger ribonucleic acid. Furthermore, in a dose-dependent manner, GnRH agonist (leuprolide acetate) inhibited, but GnRH antagonist [D-pGlu1,D-Phe2,D-Trp3.6] (GnRH-Ant1) stimulated, the rate of [3H]thymidine incorporation into myometrial smooth muscle cells (P < 0.05), whereas GnRH-Ant2 (Ac-D-P-Cl-Phe1.2,D-Trp3,D-Arg6,D-Ala10) had no effect. 17 beta-Estradiol (E2) medroxyprogesterone acetate (MPA), and E2 plus MPA (1 micromol/L) stimulated the rate of DNA synthesis by smooth muscle cells (P < 0.05), which was inhibited by GnRH analogs used at 5 micromol/L (P < 0.05). GnRH analogs had no significant effect on myometrial smooth muscle cell proliferation, with the exception of GnRH-Ant1; however, they inhibited the stimulatory action of E2, MPA, and E2 plus MPA in a time-dependent manner (P < 0.05). These cells also synthesized and released approximately 1.32 +/- 0.02 ng/mL total (active plus latent) TGF beta 1, of which 0.73 +/- 0.02 ng/mL was in an active form. E2, MPA, E2 plus MPA, and GnRH analog treatments resulted in an increase in total TGF beta 1 production, whereas GnRH agonist and GnRH-Ant2, but not GnRH-An1, inhibited active TGF beta 1 (P < 0.05). GnRH analogs also inhibited the action of E2 plus MPA on total and active TGF beta 1 production, whereas GnRH-Ant1 further stimulated E2, MPA, or E2 plus MPA action on active TGF beta 1 production (P < 0.05). The data demonstrate for the first time that GnRH and GnRH receptor messenger ribonucleic acid are expressed in myometrium, leiomyomata, and myometrial smooth muscle cells. The local expression of GnRH and receptor along with the direct action of GnRH analogs on the smooth muscle cell DNA synthesis and TGF beta 1 production suggest an autocrine/paracrine role for GnRH in these tissues, a mechanism that may be involved in leiomyomata regression in women receiving GnRH agonist therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784072     DOI: 10.1210/jcem.81.9.8784072

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Gonadotropin-releasing hormone messenger ribonucleic acid and protein expression in Vero cells.

Authors:  H Y Huang; F Raga; J S Kruessel; Y Wen; Y K Soong; M L Polan
Journal:  J Assist Reprod Genet       Date:  2001-05       Impact factor: 3.412

2.  Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells.

Authors:  Desireé M McCarthy-Keith; Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Fertil Steril       Date:  2011-04-15       Impact factor: 7.329

3.  Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma.

Authors:  John M Norian; Carter M Owen; Juan Taboas; Casey Korecki; Rocky Tuan; Minnie Malik; William H Catherino; James H Segars
Journal:  Matrix Biol       Date:  2011-09-24       Impact factor: 11.583

4.  Association of controlled ovarian hyperstimulation treatment with down-regulation of key regulators involved in embryonic implantation in mice.

Authors:  Min Xiong; Hanwang Zhang; Lei Jin; Jihui Ai; Zhiyong Huang; Guijin Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

5.  Expression of gonadotropin-releasing hormone receptor and effect of gonadotropin-releasing hormone analogue on proliferation of cultured gastric smooth muscle cells of rats.

Authors:  Lei Chen; Hong-Xuan He; Xu-De Sun; Jing Zhao; Li-Hong Liu; Wei-Quan Huang; Rong-Qing Zhang
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

6.  Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.

Authors:  I Chatzistamou; A V Schally; B Sun; P Armatis; K Szepeshazi
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

7.  Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells.

Authors:  Xiaoping Luo; Jingxia Xu; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2003-12-16       Impact factor: 5.211

8.  Gonadotrophin-releasing hormone (GnRH) analogues in the treatment of mixed mullerian tumours of the uterus: two case reports and review.

Authors:  M Katesmark; F Lawton
Journal:  Sarcoma       Date:  1998

9.  Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol.

Authors:  Maryam Eftekhar; Razieh Dehghani Firouzabadi; Hesamoddin Karimi; Elham Rahmani
Journal:  Iran J Reprod Med       Date:  2012-07

10.  Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice.

Authors:  Anki Knutsson; Sabrina Hsiung; Selvi Celik; Sara Rattik; Ingrid Yao Mattisson; Maria Wigren; Howard I Scher; Jan Nilsson; Anna Hultgårdh-Nilsson
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.